Roche Acquires Ignyta for $1.7B

Dec 26, 2017

Roche has announced plans to buy U.S. cancer drugmaker Ignyta Inc for $1.7 billion. The move is meant to increase the company's global oncology portfolio.

Ignyta's operations will continue in San Diego alongside its study of entrectinib, the company's most advanced drug.

The deal is expected to close in the first half of 2018.

Read the CNBC report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments